Related Experiment Video
Updated: Feb 22, 2026
03:43
Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
Published on: August 22, 2025
582
Exogenous Cannabinoid Efficacy: Merely a Pharmacokinetic Interaction?
Jennifer H Martin1,2,3, Jennifer Schneider4, Catherine J Lucas5
1School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia. jen.martin@newcastle.edu.au.
Clinical Pharmacokinetics
|September 19, 2017
Summary
Endocannabinoid pharmacology is well understood, but exogenous cannabinoids require further study. This research aims to clarify cannabinoid pharmacokinetics and dynamics for therapeutic development.
Area of Science:
- Pharmacology
- Neuroscience
- Drug Development
Background:
- Endocannabinoid system (ECS) pharmacology, including neurotransmitters and receptors, is largely understood.
- Endogenous cannabinoids play roles in immune, pain, and appetite pathways.
- Renewed clinical interest in exogenous cannabinoids contrasts with limited knowledge of their complex pharmacology.
Purpose of the Study:
- To review essential pharmacological knowledge for exploring cannabinoid toxicity and efficacy.
- To guide the development of therapeutic agents targeting the ECS.
- To inform the study of exogenous cannabinoids, their formulations, and whole-plant use.
Main Methods:
- Literature review of endocannabinoid and exogenous cannabinoid pharmacology.
- Analysis of pharmacokinetic and pharmacodynamic principles.
- Discussion of drug development standards for plant-derived compounds.
Main Results:
- Detailed understanding of endogenous cannabinoid pathways and their therapeutic targets.
- Identification of knowledge gaps in exogenous cannabinoid pharmacokinetics and dynamics.
- Established framework for evaluating cannabinoid efficacy and safety.
Conclusions:
- Further research into exogenous cannabinoid pharmacology is crucial for therapeutic advancement.
- Standard drug development principles must be applied to cannabinoids and their formulations.
- Blinded, placebo-controlled studies are essential for rigorous evaluation.
Related Concept Videos
01:25Pharmacokinetics: Drug–Drug Interactions
514
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
514
01:26Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect
35
The pharmacokinetic-pharmacodynamic (PK-PD) relationship describes the intricate link between drug exposure, efficacy, and toxicity, forming the foundation for optimal dosing regimens. This relationship uses mathematical modeling to characterize drug concentration-effect dynamics, ensuring precise therapeutic outcomes.Exposure represents the pharmacokinetic aspect of the PK-PD relationship, denoting the drug amount that elicits a biological response. It is typically quantified by administered...
35
01:26Pharmacokinetics: Drug–Food and Drug–Viral Interactions
306
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
306
01:14Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
34
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
34
01:14Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model
30
The link model is a fundamental pharmacokinetic-pharmacodynamic (PK–PD) approach to account for delayed drug responses when the observed effect does not immediately correlate with the drug's plasma concentration peak. This delay is mathematically addressed by introducing an effect compartment concentration, Ce, which is kinetically linked to the plasma concentration, Cp, via a first-order rate constant, ke0. The linkage allows for a more accurate prediction of drug effects over time. A...
30
01:28Pharmacokinetic–Pharmacodynamic Relationship: Dose to Pharmacological Effect
34
A drug’s dosage and pharmacokinetic properties determine how quickly it acts, how intense its effects are, and how long it lasts. Higher doses increase drug concentration at receptor sites, producing a hyperbolic curve when pharmacologic response is plotted against drug dose. Converting this scale to a log-linear format results in a sigmoidal curve, better representing dose–response relationships.For drugs following a one-compartment model, the pharmacologic response is directly...
34